Article information
Full text is only aviable in PDF
References
[1.]
European Dermatology Forum (EDF) White Book: Skin Diseases in Europe. Available at: www.euroderm.org.
[2.]
J.M. De Moragas.
Perspectivas en Dermatopatología.
Actas Dermosifiliogr, 78 (1987), pp. 7-69
[3.]
I. Sabroe, D.H. Dockrell, S.N. Vogel, S.A. Renshaw, M.K. Whyte, S.K. Dower.
Identifying and hurdling obstacles to translational research.
Nat Rev Immunol, 7 (2007), pp. 77-82
[5.]
E. Guttman-Yassky, J.G. Krueger.
Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research.
Br J Dermatol, 157 (2007), pp. 1103-1115
[6.]
R.P. Numerof, K. Asadullah.
Cytokines and anti-cytokine therapies for psoriasis and atopic dermatitits.
BioDrugs, 20 (2006), pp. 93-103
[7.]
A.B. Gottlien, F. Chamian, S. Masud, I. Cardinale, M.V. Abello, M.A. Lowes, et al.
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
J Immunol, 175 (2005), pp. 2721-2729
[8.]
E. Toichi, G. Torres, T.S. McCormick, T. Chang, M.A. Mascelli, C.L. Kauffman, et al.
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
J Immunol, 177 (2006), pp. 4917-4926
[9.]
T. Jung, G. Stingl.
Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.
J Allergy Clin Immunol, 122 (2008), pp. 1074-1081
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
